

# J Scott Miners

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1722129/publications.pdf>

Version: 2024-02-01

45  
papers

2,710  
citations

172457

29  
h-index

223800

46  
g-index

47  
all docs

47  
docs citations

47  
times ranked

4157  
citing authors

#	ARTICLE	IF	CITATIONS
1	A $\beta$ -Degrading Enzymes: Potential for Treatment of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 944-959.	1.7	228
2	Cerebrovascular disease in ageing and Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 131, 645-658.	7.7	218
3	Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid- $\beta$ and tau pathology. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 50.	6.2	159
4	Cognitive impact of COVID-19: looking beyond the short term. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 170.	6.2	149
5	Differing associations between A $\beta$ accumulation, hypoperfusion, blood-brain barrier dysfunction and loss of PDGFR $\beta$ pericyte marker in the precuneus and parietal white matter in Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 103-115.	4.3	147
6	Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE to cerebral amyloid angiopathy. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 181-193.	3.2	136
7	Decreased Expression and Activity of Neprilysin in Alzheimer Disease Are Associated With Cerebral Amyloid Angiopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 1012-1021.	1.7	132
8	ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2020, 139, 485-502.	7.7	101
9	Neprilysin and Insulin-Degrading Enzyme Levels Are Increased in Alzheimer Disease in Relation to Disease Severity. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 902-914.	1.7	95
10	Changes with Age in the Activities of $\beta$ -Secretase and the A $\beta$ -Degrading Enzymes Neprilysin, Insulin-Degrading Enzyme and Angiotensin-Converting Enzyme. <i>Brain Pathology</i> , 2010, 20, 794-802.	4.1	82
11	Pathophysiology of Hypoperfusion of the Precuneus in Early Alzheimer's Disease. <i>Brain Pathology</i> , 2016, 26, 533-541.	4.1	81
12	Evaluating the relationship between amyloid- $\beta$ and $\tau$ -synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 77.	6.2	74
13	CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 81.	6.2	72
14	BIN1 Is Decreased in Sporadic but Not Familial Alzheimer's Disease or in Aging. <i>PLoS ONE</i> , 2013, 8, e78806.	2.5	65
15	Inhibition of Coxsackie B Virus Infection by Soluble Forms of Its Receptors: Binding Affinities, Altered Particle Formation, and Competition with Cellular Receptors. <i>Journal of Virology</i> , 2005, 79, 12016-12024.	3.4	61
16	Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of A $\beta$ . <i>Brain Pathology</i> , 2017, 27, 305-313.	4.1	59
17	Oligomeric A $\beta$ in Alzheimer's Disease: Relationship to Plaque and Tangle Pathology, APOE Genotype and Cerebral Amyloid Angiopathy. <i>Brain Pathology</i> , 2010, 20, 468-480.	4.1	57
18	Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease. <i>Brain Pathology</i> , 2016, 26, 607-617.	4.1	57

#	ARTICLE	IF	CITATIONS
19	Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid- $\beta^2$ ( $A\beta^2$ ) Plaque Load and $A\beta^2$ -Synthesizing and $A\beta^2$ -Degrading Enzymes in Frontal Cortex. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1191-1203.	2.6	46
20	Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. <i>Journal of Neuroscience Methods</i> , 2008, 167, 229-236.	2.5	41
21	Higher Soluble Amyloid $\beta^2$ Concentration in Frontal Cortex of Young Adults than in Normal Elderly or Alzheimer's Disease. <i>Brain Pathology</i> , 2010, 20, 787-793.	4.1	41
22	Oxidative Balance in Alzheimer's Disease: Relationship to APOE, Braak Tangle Stage, and the Concentrations of Soluble and Insoluble Amyloid- $\beta^2$ . <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1363-1373.	2.6	41
23	Convection-Enhanced Delivery of Neprilysin: A Novel Amyloid- $\beta^2$ -Degrading Therapeutic Strategy. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 43-56.	2.6	39
24	$A\beta^2$ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 238.	3.4	39
25	Neprilysin Protects against Cerebral Amyloid Angiopathy and $A\beta^2$ -Induced Degeneration of Cerebrovascular Smooth Muscle Cells. <i>Brain Pathology</i> , 2011, 21, 594-605.	4.1	38
26	Mediators of cerebral hypoperfusion and blood-brain barrier leakiness in Alzheimer's disease, vascular dementia and mixed dementia. <i>Brain Pathology</i> , 2021, 31, e12935.	4.1	38
27	Angiotensin-III is Increased in Alzheimer's Disease in Association with Amyloid- $\beta^2$ and Tau Pathology. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 203-214.	2.6	37
28	Prion Protein Is Decreased in Alzheimer's Brain and Inversely Correlates with BACE1 Activity, Amyloid- $\beta^2$ Levels and Braak Stage. <i>PLoS ONE</i> , 2013, 8, e59554.	2.5	35
29	Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer's disease. <i>Brain</i> , 2021, 144, 1869-1883.	7.6	32
30	ACE variants and association with brain $A\beta^2$ levels in Alzheimer's disease. <i>American Journal of Translational Research (discontinued)</i> , 2010, 3, 73-80.	0.0	32
31	Accumulation of Insoluble Amyloid- $\beta^2$ in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 101-108.	2.6	30
32	White Matter Hypoperfusion and Damage in Dementia: Post-Mortem Assessment. <i>Brain Pathology</i> , 2015, 25, 99-107.	4.1	30
33	Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 317-327.	3.2	29
34	Pathological changes within the cerebral vasculature in Alzheimer's disease: New perspectives. <i>Brain Pathology</i> , 2022, 32, e13061.	4.1	28
35	Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. <i>Journal of Neuroscience Methods</i> , 2008, 169, 177-181.	2.5	26
36	Angiotensin II-inhibiting drugs have no effect on intraneuronal $A\beta^2$ or oligomeric $A\beta^2$ levels in a triple transgenic mouse model of Alzheimer's disease. <i>American Journal of Translational Research (discontinued)</i> , 2011, 3, 197-208.	0.0	22

#	ARTICLE	IF	CITATIONS
37	Small vessel disease, neurovascular regulation and cognitive impairment: post-mortem studies reveal a complex relationship, still poorly understood. <i>Clinical Science</i> , 2017, 131, 1579-1589.	4.3	19
38	Investigation of $\tau$ phosphorylated at serine 8 (p $\tau$ ) in Alzheimer's disease, dementia with Lewy bodies and vascular dementia. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 428-444.	3.2	16
39	Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of $\tau$ -synuclein in multiple system atrophy. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 347-360.	3.2	16
40	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 525-535.	2.6	16
41	Accumulation of $\tau$ -synuclein in dementia with Lewy bodies is associated with decline in the $\tau$ -synuclein-degrading enzymes kallikrein-6 and calpain-1. <i>Acta Neuropathologica Communications</i> , 2014, 2, 164.	5.2	13
42	Pericyte Contractile Responses to Endothelin-1 and A $\beta$ Peptides: Assessment by Electrical Impedance Assay. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 723953.	3.7	10
43	Dysregulation of ACE-1 in Normal Aging and the Early Stages of Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 1775-1783.	3.6	10
44	Endothelin-converting enzymes degrade $\tau$ -synuclein and are reduced in dementia with Lewy bodies. <i>Journal of Neurochemistry</i> , 2017, 141, 275-286.	3.9	7
45	Divergence in the activity of the N- and C- catalytic domains of ACE1 - implications for the role of the renin-angiotensin system in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 57.	5.2	5